

Title (en)
LIPOSOMAL OZONE NANOSOLUTIONS

Title (de)
LIPOSOMALE OZON-NANOLÖSUNGEN

Title (fr)
NANOSOLUTIONS D'OZONE LIPOSOMALES

Publication
EP 4203920 A4 20240501 (EN)

Application
EP 22763707 A 20220301

Priority
• TR 202104032 A 20210301
• TR 2022050177 W 20220301

Abstract (en)
[origin: WO2022186802A1] The present invention relates to liposomal ozone nanosolutions with antiviral, antifungal and antibacterial effects; wound healing, tissue healing properties suitable for use in human, veterinary, food, agriculture and chemistry and cosmetics fields. The inventive liposomal ozone nanosolution can be used as nasal spray, mouth spray, ear drops, eye drops, hand and face disinfectant, vaginal, intravesical, rectal solutions, intraarticular, subcutaneous, intramuscular, intravenous injection solutions for human and veterinary hygiene purposes and can be used as a surface cleaner as well. The effectiveness of the inventive liposomal ozone nanosolutions has been proven on viruses such as influenza or corona virus, especially Sars-Cov-2 and bacteria, especially Staphylococcus aureus and Escherichia coli.

IPC 8 full level
A61K 9/107 (2006.01); **A01N 25/04** (2006.01); **A61K 33/40** (2006.01); **A61K 47/44** (2017.01)

CPC (source: EP)
A01N 31/08 (2013.01); **A01N 37/02** (2013.01); **A01N 37/16** (2013.01); **A01N 43/90** (2013.01); **A01N 53/00** (2013.01); **A01N 59/00** (2013.01); **A01N 65/22** (2013.01); **A01N 65/36** (2013.01); **A01P 1/00** (2021.08); **A01P 3/00** (2021.08); **A01P 5/00** (2021.08); **A01P 7/02** (2021.08); **A61K 9/0014** (2013.01); **A61K 9/0019** (2013.01); **A61K 9/1075** (2013.01); **A61K 9/127** (2013.01); **A61K 33/40** (2013.01); **A61K 45/06** (2013.01); **A61K 47/10** (2013.01); **A61K 47/26** (2013.01); **A61K 47/44** (2013.01)

C-Set (source: EP)
1. **A01N 59/00 + A01N 25/30 + A01N 31/08 + A01N 37/02 + A01N 43/90 + A01N 53/00**
2. **A01N 59/00 + A01N 25/04 + A01N 25/30 + A01N 65/22 + A01N 65/36**
3. **A01N 65/36 + A01N 25/04 + A01N 25/30**
4. **A01N 65/22 + A01N 25/04 + A01N 25/30**
5. **A01N 37/02 + A01N 25/04 + A01N 25/30 + A01N 31/08 + A01N 43/90 + A01N 53/00**
6. **A01N 31/08 + A01N 25/04 + A01N 25/30 + A01N 43/90 + A01N 53/00**
7. **A01N 43/90 + A01N 25/04 + A01N 25/30 + A01N 53/00**
8. **A01N 53/00 + A01N 25/04 + A01N 25/30**
9. **A01N 37/16 + A01N 25/04 + A01N 25/30 + A01N 31/08 + A01N 43/90 + A01N 53/00**

Citation (search report)
• [Y] WO 2016120478 A1 20160804 - WINKELMANN WOLFGANG [DE]
• [Y] WO 2019240713 A2 20191219 - SABANCI AHMET UEMIT [TR]
• [Y] WO 2018020456 A1 20180201 - FB VISION S R L [IT]
• [XY] SALGO MARIA GIULIA ET AL: "Activation of Phospholipase A2 in 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine Liposomes Containing Lipid Ozonation Products", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 7, no. 3, 1 May 1994 (1994-05-01), US, pages 458 - 462, XP093133351, ISSN: 0893-228X, DOI: 10.1021/tx00039a026
• [XY] SALGO MARIA G. ET AL: "Effect of lipid ozonation products on liposomal membranes detected by Laurdan fluorescence", FREE RADICAL BIOLOGY & MEDICINE, vol. 19, no. 5, 1 November 1995 (1995-11-01), US, pages 609 - 616, XP093133540, ISSN: 0891-5849, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0891584995000748/pdf?md5=1bcfd6d740c5a2e8f3698b6b3c5633d&pid=1-s2.0-0891584995000748-main.pdf> DOI: 10.1016/0891-5849(95)00074-8
• See also references of WO 2022186802A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2022186802 A1 20220909; EP 4203920 A1 20230705; EP 4203920 A4 20240501

DOCDB simple family (application)
TR 2022050177 W 20220301; EP 22763707 A 20220301